CPG
CORT icon

Cornerstone Planning Group’s Corcept Therapeutics CORT Stock Holding History

Cornerstone Planning Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$636 Buy
+7
New +$423 ﹤0.01% 1627
2025
Q4 		– Sell
-6
Closed -$434 – 1738
2025
Q3 		$434 Hold
6
– – ﹤0.01% 1510
2025
Q2 		$423 Hold
6
– – ﹤0.01% 1345
2025
Q1 		$416 Hold
6
– – ﹤0.01% 1349
2024
Q4 		$362 Buy
+6
New +$314 ﹤0.01% 1228

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Cornerstone Planning Group's CORT Position: Q2 2026 in Review

Cornerstone Planning Group opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 7 shares worth $636. The stake represents ﹤0.01% of the portfolio and ranks #1627 among its holdings. This is a return to the name: Cornerstone Planning Group previously reported a position in CORT as recently as Q3 2025.

Cornerstone Planning Group first reported a position in CORT in Q4 2024 and has held it in 5 quarters since. 188 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Cornerstone Planning Group held 7 shares of Corcept Therapeutics worth $636 as of Q2 2026.
  • Corcept Therapeutics was a new Cornerstone Planning Group position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1627 holding.
  • Cornerstone Planning Group first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 188 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.